Best Peptides for Weight Loss in 2026: Science-Backed Rankings

The best peptides for weight loss have changed the entire landscape of obesity treatment. GLP-1 receptor agonists like semaglutide and tirzepatide now deliver 15-22% body weight loss in clinical trials — results that were unimaginable just a decade ago.

But here’s the problem: search “weight loss peptides” online and you’ll find everything from FDA-approved medications to unproven research compounds lumped together as if they’re all equally effective. They’re not. Not even close.

This guide ranks the best peptides for weight loss based on one thing: what the actual research shows. We’ll cover which peptides have strong clinical evidence, which are still experimental, and which ones the data doesn’t support — so you can make informed decisions rather than chasing hype.

How Peptides Cause Weight Loss

Weight loss peptides work through several distinct biological mechanisms. Understanding these pathways helps explain why some peptides produce dramatic results while others show modest or unproven effects.

The most effective weight loss peptides target the incretin system — a hormone pathway that connects your gut, brain, and pancreas to regulate appetite and metabolism. When you eat, your gut releases incretin hormones like GLP-1 (glucagon-like peptide-1) that signal your brain to feel full and tell your pancreas to manage blood sugar.

GLP-1 receptor agonists — the class that includes semaglutide and tirzepatide — are synthetic peptides that mimic and amplify this natural system. They work through three main pathways:

1. Appetite suppression in the brain. GLP-1 receptors sit in the hypothalamus, the brain region that controls hunger. When activated, they switch on POMC/CART neurons (the “stop eating” signal) and quiet NPY/AgRP neurons (the “keep eating” signal). The result: you genuinely feel less hungry and more satisfied with smaller meals (Kanoski et al., 2016).

2. Slower gastric emptying. These peptides slow down how quickly food leaves your stomach. This creates a prolonged feeling of physical fullness after eating, even with smaller portions. Think of it like a traffic light turning red in your digestive system — everything slows down, keeping you satisfied longer.

3. Improved metabolic regulation. GLP-1 peptides enhance insulin secretion (but only when blood sugar is elevated), suppress glucagon release, and improve how your body processes nutrients. This means less excess glucose gets converted to fat storage (Zhao et al., 2024).

Other peptide categories approach fat loss differently. Growth hormone secretagogues like CJC-1295/Ipamorelin stimulate your pituitary gland to release more growth hormone, which indirectly supports fat metabolism. And specialized peptides like AOD-9604 target fat tissue directly by stimulating lipolysis (the breakdown of stored fat).

The critical difference? GLP-1 peptides have been validated in trials with thousands of participants and years of follow-up data. Most other weight loss peptides have far less evidence behind them.

Best Peptides for Weight Loss: The Rankings

We’ve organized these peptides into three tiers based on the strength and quality of their clinical evidence — not marketing claims or user testimonials.

Tier 1: Strong Clinical Evidence

1. Tirzepatide (Zepbound/Mounjaro) — Up to 22.5% Weight Loss

Tirzepatide earns the top spot because it produces the greatest weight loss of any currently approved medication, and it beat semaglutide head-to-head in a clinical trial.

What it is: A dual GIP/GLP-1 receptor agonist — sometimes called a “twincretin” because it activates two incretin receptors instead of one. Manufactured by Eli Lilly, approved as Zepbound for weight management in November 2023.

How it works: By activating both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously, tirzepatide amplifies appetite suppression and metabolic effects beyond what single-receptor drugs achieve. The GIP receptor activation may also enhance fat oxidation through direct signaling in adipose tissue.

The evidence:

The SURMOUNT-1 trial enrolled 2,539 adults with obesity (no diabetes) and tested three doses over 72 weeks. At the highest dose (15 mg), participants lost an average of 22.5% of their body weight — about 52 pounds (24 kg). Even the lowest dose (5 mg) produced 16% weight loss. Ninety-six percent of people on the higher doses lost at least 5% of their body weight (Jastreboff et al., 2022).

A body composition sub-study found that approximately 75% of the weight lost was fat mass and 25% was lean mass — a ratio consistent across both treatment and placebo groups (SURMOUNT-1 body composition data, 2025).

The SURMOUNT-5 head-to-head trial directly compared tirzepatide against semaglutide over 72 weeks. Tirzepatide produced 20.2% weight loss compared to 13.7% with semaglutide — a 47% greater relative reduction. More participants on tirzepatide reached every weight loss threshold: 82% lost at least 10% of body weight versus 61% on semaglutide (SURMOUNT-5, NEJM 2025).

Long-term maintenance data from SURMOUNT-4 showed that continued tirzepatide use over 88 weeks maintained a total weight reduction of 25.3%, while those switched to placebo regained significant weight (SURMOUNT-4, 2023).

Administration: Once-weekly subcutaneous injection. Doses: 5 mg, 10 mg, or 15 mg.

Key consideration: Like all GLP-1-class medications, gastrointestinal side effects (nausea, diarrhea, constipation) are common, especially during dose escalation. Most side effects are mild-to-moderate and improve over time.

2. Semaglutide (Wegovy/Ozempic) — 15-21% Weight Loss

Semaglutide is the peptide that put weight loss medications in the mainstream spotlight. It was the first GLP-1 receptor agonist to demonstrate truly significant weight loss in large-scale trials.

What it is: A GLP-1 receptor agonist approved as Wegovy for chronic weight management (June 2021). Originally developed for type 2 diabetes as Ozempic. Manufactured by Novo Nordisk.

How it works: Semaglutide mimics natural GLP-1 hormone with structural modifications that extend its half-life to about one week. It activates GLP-1 receptors in the hypothalamus to suppress appetite, slows gastric emptying, and improves insulin dynamics.

The evidence:

The landmark STEP 1 trial tested semaglutide 2.4 mg in 1,961 adults with obesity across 129 sites in 16 countries. Over 68 weeks, participants lost an average of 14.9% of their body weight compared to 2.4% on placebo. More than half (50.5%) lost at least 15% of their body weight (Wilding et al., NEJM 2021).

Two-year data from STEP 5 confirmed the weight loss was sustained, with participants maintaining an average 15.2% reduction at 104 weeks (STEP 5, 2022).

A higher 7.2 mg dose tested in the STEP UP trial achieved 20.7% weight loss at 72 weeks in the adherent population — with over 90% of participants losing at least 5% of their body weight, and roughly one-third losing 25% or more (Wharton et al., Lancet D&E 2025).

Across the STEP trial program (STEP 1, 3, 4, and 8), the standard 2.4 mg dose consistently produced 14.9-17.4% weight loss at 68 weeks, with 69-79% of participants achieving at least 10% reduction.

Administration: Once-weekly subcutaneous injection. Standard dose: 2.4 mg (titrated up from 0.25 mg over 16-20 weeks).

Key consideration: STEP 4 showed that weight regain occurs when semaglutide is discontinued (Rubino et al., 2021), suggesting ongoing treatment may be needed to maintain results. Oral semaglutide formulations became widely available in early 2026, expanding access options.

3. Retatrutide — Up to 28.7% Weight Loss (Investigational)

Retatrutide represents the next frontier in weight loss peptides. Still in clinical trials, it has already produced the highest weight loss percentages ever recorded for any anti-obesity medication.

What it is: A triple hormone receptor agonist (GIP/GLP-1/glucagon) being developed by Eli Lilly. Not yet FDA-approved — currently in Phase 3 trials.

How it works: Retatrutide activates three receptors simultaneously, adding glucagon receptor activation on top of the dual GIP/GLP-1 mechanism. The glucagon component is the game-changer: it directly increases energy expenditure by stimulating hepatic lipid oxidation (your liver burns more fat for energy) and thermogenesis (your body generates more heat, burning additional calories). This creates a dual attack — reducing calorie intake through appetite suppression while also increasing calorie burning.

The evidence:

The Phase 2 trial enrolled 338 adults with obesity and tested multiple doses over 48 weeks. The highest dose (12 mg) produced 24.2% weight loss — and weight loss curves had not yet plateaued at 48 weeks, suggesting even greater reductions with longer treatment. One hundred percent of participants on the 12 mg dose lost at least 5% of body weight, and 83% lost at least 15% (Jastreboff et al., NEJM 2023).

The first Phase 3 result (TRIUMPH-4) tested retatrutide in adults with obesity and knee osteoarthritis over 68 weeks. The 12 mg dose group lost an average of 28.7% of body weight — approximately 71.2 pounds. Participants also experienced substantial pain relief, with knee pain scores improving by up to 75.8%.

Beyond weight loss, Phase 2 data showed metabolic improvements: total cholesterol reductions of 15-18%, LDL cholesterol reductions of 12-22%, and triglyceride reductions of 35-40%. A separate trial is studying retatrutide’s effects on metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease (MASLD trial, 2024).

Current status: The Phase 3 TRIUMPH program enrolled over 5,800 participants and is studying retatrutide across seven indications including obesity, type 2 diabetes, cardiovascular outcomes, and sleep apnea. Seven additional Phase 3 readouts are expected in 2026.

Key consideration: Retatrutide is not yet available for prescription. It is still investigational and cannot be legally obtained outside of clinical trials. The gastrointestinal side effects appear similar to other incretin-based drugs.

Tier 2: FDA-Approved for Related Conditions

4. Tesamorelin (Egrifta) — 15% Visceral Fat Reduction

Tesamorelin occupies a unique space: it’s FDA-approved and has solid clinical data, but for a specific condition rather than general weight loss.

What it is: A growth hormone-releasing hormone (GHRH) analog, approved in 2010 as Egrifta for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Manufactured by Theratechnologies. An updated weekly formulation (Egrifta WR) was approved in March 2025.

How it works: Tesamorelin stimulates your pituitary gland to produce and release more endogenous growth hormone. The additional GH then mobilizes visceral fat — the deep abdominal fat that wraps around organs and drives metabolic disease. Importantly, it stimulates your own natural GH production rather than introducing synthetic growth hormone directly.

The evidence:

The pivotal Phase III trial enrolled 404 HIV-infected patients with excess abdominal fat. Over 12 months, tesamorelin reduced visceral adipose tissue by 15.2% while the placebo group saw a 5.0% increase. Triglycerides also decreased significantly (Falutz et al., NEJM).

Six-month data from an earlier trial showed a 10.9% visceral fat reduction (21 cm² decrease) with tesamorelin versus essentially no change with placebo (Falutz et al., 2010).

Follow-up research linked visceral fat reduction to broader metabolic improvements including better triglyceride levels, increased adiponectin, and preserved glucose homeostasis (metabolic profile study, 2012).

Important limitations:

• FDA-approved only for HIV-associated lipodystrophy — not for general weight loss
• Selectively targets visceral fat; does not significantly reduce subcutaneous fat or total body weight
• Off-label use for body composition is common but falls outside the approved indication
• Requires daily subcutaneous injection (original formulation)
• Weight regain occurs upon discontinuation

Tier 3: Research-Stage Peptides

These peptides are marketed by vendors for weight loss purposes, but their evidence base ranges from limited to nonexistent in humans. We include them because you’ll encounter them frequently online — understanding their actual evidence level helps you make informed decisions.

5. AOD-9604 — Limited Evidence, Development Terminated

What it is: A synthetic fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity drug in the 1990s.

How it works: AOD-9604 mimics the fat-burning region of growth hormone without activating the full GH receptor. In theory, it stimulates lipolysis in fat tissue while avoiding GH side effects like blood sugar disruption or cell proliferation.

The evidence:

Preclinical studies showed promising results: AOD-9604 reduced body weight gain and increased fat oxidation in obese mice without causing hyperglycemia — a significant advantage over full-length growth hormone (Heffernan et al., 2001).

However, the clinical picture was disappointing. Six human trials involving over 900 participants were conducted, but the largest Phase IIb trial failed to achieve statistical significance for its primary endpoint. The best result from an individual trial showed a modest 1.8 kg (about 4 pounds) advantage over placebo over 12 weeks. Development was terminated in 2007.

Current status: Not FDA-approved. Not approved by any major regulatory authority worldwide. Listed as a WADA prohibited substance. Available only as a “research chemical” — which means no quality control standards apply.

Bottom line: Despite widespread marketing, the clinical data for AOD-9604 as a weight loss peptide is weak. It failed in its largest trial and was abandoned by its developer.

6. CJC-1295/Ipamorelin — Indirect Approach, Limited Direct Evidence

What it is: A combination of two growth hormone secretagogues. CJC-1295 is a long-acting GHRH analog; ipamorelin is a selective growth hormone secretagogue receptor agonist.

How it works: CJC-1295 extends baseline growth hormone elevation (its half-life is 5.8-8.1 days), while ipamorelin triggers acute GH pulses that mimic natural secretion patterns. Together, they amplify GH output, and elevated growth hormone supports lipolysis and lean body mass preservation.

The evidence:

CJC-1295 has been shown to increase GH levels by 2- to 10-fold and IGF-1 levels by 1.5- to 3-fold in healthy adults, with effects lasting 6+ days after a single injection (Teichman et al., 2006). Ipamorelin is notable as the first selective GH secretagogue — it releases growth hormone without significantly affecting cortisol or prolactin (Raun et al., 1998).

However, there are no published randomized controlled trials demonstrating direct weight or fat loss from the CJC-1295/ipamorelin combination in healthy adults. The fat loss rationale is extrapolated from what we know about growth hormone physiology, not from direct evidence for this specific combination.

Current status: Neither peptide is FDA-approved for any indication. The FDA has flagged both for safety concerns in compounding contexts (2024). Available through compounding pharmacies and research vendors.

7. 5-Amino-1MQ — Preclinical Only

What it is: A small molecule that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme involved in fat cell metabolism.

How it works: By blocking NNMT, 5-Amino-1MQ increases intracellular NAD+ levels (boosting cellular energy metabolism), suppresses lipogenesis (fat creation), and reduces fat cell size. In animal studies, it reduced body fat without affecting food intake — suggesting it targets fat storage directly rather than appetite.

The evidence:

The key preclinical study treated diet-induced obese mice with 5-Amino-1MQ for 11 days. The compound significantly reduced body weight, white adipose tissue mass, and fat cell size with no observable adverse effects and no change in food intake (Neelakantan et al., 2018). A follow-up study found that combining NNMT inhibition with a low-fat diet normalized body composition in obese mice to lean-animal levels (Neelakantan et al., 2022).

Critical limitation: No human clinical trial data exists. Zero. All findings come from cell cultures and mouse models. Many compounds that work well in mice fail completely in human trials.

Current status: Not FDA-approved. Sold as a “research chemical.” No human safety data available.

8. MOTS-c — Early Research Stage

What it is: A 16-amino-acid peptide encoded by mitochondrial DNA, described as an “exercise mimetic” because it replicates some metabolic effects of physical exercise.

How it works: MOTS-c activates AMPK (AMP-activated protein kinase), a master metabolic switch that stimulates glucose utilization and fat oxidation. It targets skeletal muscle primarily and has been shown to prevent diet-induced obesity and insulin resistance in animal models.

The evidence:

The discovery study demonstrated that MOTS-c treatment prevented both age-related and high-fat-diet-induced obesity and insulin resistance in mice (Lee et al., Cell Metabolism 2015). Exercise research has shown that MOTS-c levels increase 11.9-fold in skeletal muscle and 1.5-fold in circulation after physical activity in humans (Reynolds et al., 2019).

Critical limitation: No approved therapeutic applications. Human studies are limited to observational data on endogenous MOTS-c levels — nobody has published controlled trial data on exogenous MOTS-c administration for weight loss in humans.